Suppr超能文献

血清白蛋白的氨甲酰化与终末期肾病的促红细胞生成素抵抗。

Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease.

机构信息

Department of Medicine, Division of Nephrology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts;, †Department of Pathology, Division of Clinical Chemistry and, ‡Department of Medicine, Division of Nephrology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.

出版信息

Clin J Am Soc Nephrol. 2013 Nov;8(11):1927-34. doi: 10.2215/CJN.04310413. Epub 2013 Aug 22.

Abstract

BACKGROUND AND OBJECTIVES

The mechanisms underlying erythropoietin resistance are not fully understood. Carbamylation is a post-translational protein modification that can alter the function of proteins, such as erythropoietin. The hypothesis of this study is that carbamylation burden is independently associated with erythropoietin resistance.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a nonconcurrent prospective cohort study of incident hemodialysis patients in the United States, carbamylated albumin, a surrogate of overall carbamylation burden, in 158 individuals at day 90 of dialysis initiation and erythropoietin resistance index (defined as average weekly erythropoietin dose [U] per kg body weight per hemoglobin [g/dl]) over the subsequent 90 days were measured. Linear regression was used to describe the relationship between carbamylated albumin and erythropoietin resistance index. Logistic regression characterized the relationship between erythropoietin resistance index, 1-year mortality, and carbamylation.

RESULTS

The median percent carbamylated albumin was 0.77% (interquartile range=0.58%-0.93%). Median erythropoietin resistance index was 18.7 units/kg per gram per deciliter (interquartile range=8.1-35.6 units/kg per gram per deciliter). Multivariable adjusted analysis showed that the highest quartile of carbamylated albumin was associated with a 72% higher erythropoietin resistance index compared with the lowest carbamylation quartile (P=0.01). Increasing erythropoietin resistance index was associated with a higher risk of death (odds ratio per unit increase in log-erythropoietin resistance index, 1.69; 95% confidence interval, 1.06 to 2.70). However, the association between erythropoietin resistance index and mortality was no longer statistically significant when carbamylation was included in the analysis (odds ratio, 1.44; 95% confidence interval, 0.87 to 2.37), with carbamylation showing the dominant association with death (odds ratio for high versus low carbamylation quartile, 4.53; 95% confidence interval, 1.20 to 17.10).

CONCLUSION

Carbamylation was associated with higher erythropoietin resistance index in incident dialysis patients and a better predictor of mortality than erythropoietin resistance index.

摘要

背景与目的

促红细胞生成素抵抗的机制尚未完全阐明。氨甲酰化是一种翻译后蛋白质修饰,可改变蛋白质的功能,如促红细胞生成素。本研究的假设是,氨甲酰化负担与促红细胞生成素抵抗独立相关。

设计、设置、参与者和测量:在美国进行的一项非同期前瞻性队列研究中,研究了 158 名新开始透析的患者在透析开始后第 90 天的白蛋白氨甲酰化(整体氨甲酰化负担的替代指标)和随后 90 天内每周平均促红细胞生成素剂量[U]与体重每克血红蛋白[g/dl]的比值(定义为促红细胞生成素抵抗指数)。线性回归用于描述白蛋白氨甲酰化与促红细胞生成素抵抗指数之间的关系。逻辑回归描述了促红细胞生成素抵抗指数、1 年死亡率和氨甲酰化之间的关系。

结果

中位白蛋白氨甲酰化百分比为 0.77%(四分位间距=0.58%-0.93%)。中位促红细胞生成素抵抗指数为 18.7 单位/kg 每克每分升(四分位间距=8.1-35.6 单位/kg 每克每分升)。多变量调整分析表明,与最低氨甲酰化四分位数相比,白蛋白氨甲酰化最高四分位数的促红细胞生成素抵抗指数高 72%(P=0.01)。促红细胞生成素抵抗指数的增加与死亡风险增加相关(每单位对数促红细胞生成素抵抗指数增加的优势比,1.69;95%置信区间,1.06 至 2.70)。然而,当分析中包括氨甲酰化时,促红细胞生成素抵抗指数与死亡率之间的关联不再具有统计学意义(优势比,1.44;95%置信区间,0.87 至 2.37),氨甲酰化与死亡的关联更为显著(高氨甲酰化四分位数与低氨甲酰化四分位数的优势比,4.53;95%置信区间,1.20 至 17.10)。

结论

在新开始透析的患者中,氨甲酰化与更高的促红细胞生成素抵抗指数相关,并且是死亡率的更好预测指标,优于促红细胞生成素抵抗指数。

相似文献

1
Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease.
Clin J Am Soc Nephrol. 2013 Nov;8(11):1927-34. doi: 10.2215/CJN.04310413. Epub 2013 Aug 22.
2
Longitudinal Changes in Protein Carbamylation and Mortality Risk after Initiation of Hemodialysis.
Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1809-1816. doi: 10.2215/CJN.02390316. Epub 2016 Jul 21.
5
Serum albumin is strongly associated with erythropoietin sensitivity in hemodialysis patients.
Clin J Am Soc Nephrol. 2008 Jan;3(1):98-104. doi: 10.2215/CJN.03330807. Epub 2007 Nov 28.
6
The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
N Engl J Med. 1996 Feb 15;334(7):420-5. doi: 10.1056/NEJM199602153340702.
7
10
No difference in meeting hemoglobin and albumin targets for dialyzed children with urologic disorders.
Pediatr Nephrol. 2011 Jul;26(7):1129-36. doi: 10.1007/s00467-011-1850-9. Epub 2011 Mar 20.

引用本文的文献

4
Metabolite profiling of CKD progression in the chronic renal insufficiency cohort study.
JCI Insight. 2022 Oct 24;7(20):e161696. doi: 10.1172/jci.insight.161696.
5
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient.
Am J Nephrol. 2022;53(5):333-342. doi: 10.1159/000523947. Epub 2022 Apr 22.
6
Blood Thiol Redox State in Chronic Kidney Disease.
Int J Mol Sci. 2022 Mar 5;23(5):2853. doi: 10.3390/ijms23052853.
7
Avenues for post-translational protein modification prevention and therapy.
Mol Aspects Med. 2022 Aug;86:101083. doi: 10.1016/j.mam.2022.101083. Epub 2022 Feb 25.
8
Carbamylated Proteins in Renal Disease: Aggravating Factors or Just Biomarkers?
Int J Mol Sci. 2022 Jan 5;23(1):574. doi: 10.3390/ijms23010574.
9
Peritoneal Protein Loss Is Not Associated With Sarcopenia in Peritoneal Dialysis Patients.
Front Med (Lausanne). 2021 Jul 14;8:653807. doi: 10.3389/fmed.2021.653807. eCollection 2021.
10
Effects of a medium cut-off (Theranova) dialyser on haemodialysis patients: a prospective, cross-over study.
Clin Kidney J. 2019 Nov 11;14(1):382-389. doi: 10.1093/ckj/sfz155. eCollection 2021 Jan.

本文引用的文献

1
Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure.
Sci Transl Med. 2013 Mar 6;5(175):175ra29. doi: 10.1126/scitranslmed.3005218.
2
Protein carbamylation predicts mortality in ESRD.
J Am Soc Nephrol. 2013 Apr;24(5):853-61. doi: 10.1681/ASN.2012030254. Epub 2013 Feb 21.
3
4
Renal anemia of inflammation: the name is self-explanatory.
Blood Purif. 2011;32(3):220-5. doi: 10.1159/000328037. Epub 2011 Aug 9.
5
Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis.
Clin Chem. 2011 Nov;57(11):1499-505. doi: 10.1373/clinchem.2011.163188. Epub 2011 Jul 18.
6
Glycated and carbamylated albumin are more "nephrotoxic" than unmodified albumin in the amphibian kidney.
Am J Physiol Renal Physiol. 2011 Sep;301(3):F476-85. doi: 10.1152/ajprenal.00342.2010. Epub 2011 Mar 2.
7
The value of failure: the discovery of TNF and its natural inhibitor erythropoietin.
J Intern Med. 2011 Jan;269(1):8-15. doi: 10.1111/j.1365-2796.2010.02319.x.
8
Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
N Engl J Med. 2010 Sep 16;363(12):1146-55. doi: 10.1056/NEJMoa1005109.
9
10
Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis.
Clin J Am Soc Nephrol. 2009 Dec;4(12):1944-53. doi: 10.2215/CJN.05560809. Epub 2009 Oct 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验